Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2016

Open Access 01-12-2016 | Primary research

Oridonin inhibits pancreatic cancer cell migration and epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling pathway

Authors: Qian-Qian Liu, Ke Chen, Qiao Ye, Xiao-Hua Jiang, Yun-Wei Sun

Published in: Cancer Cell International | Issue 1/2016

Login to get access

Abstract

Background

Oridonin (ORI) can inhibit proliferation and migration in various types of cancer cell lines. However, the exact mechanism remains unclear. We investigated the migration inhibitory effect of ORI on human pancreatic cancer SW1990 cells and dissected the possible molecular mechanism(s).

Methods

CCK-8 assay was used to observe the cell viability. Wound healing assay, transwell assay and spontaneous metastasis model were used to observe the migration activities. Real-time PCR, immunofluorescence, western blot analysis and immunohistochemistry methods were used to observe the expression of genes or proteins.

Results

ORI inhibited the migration of SW1990 cells. Real-time PCR and immuno-fluorescence analyses of epithelial-to-mesenchymal transition (EMT) markers were compared between control group and ORI group. The expression of mesenchymal molecular markers, such as vimentin, snail and slug decreased. The expression of epithelial-related marker E-cadherin increased. Wnt/β-catenin signalling was inhibited by ORI using luciferase reporter assay. ORI can decrease the β-catenin protein level not only in the nucleus, but also in the cytoplasm and the whole cell after the treatment with ORI and glycogen synthase kinase 3β (GSK3β) was increased in the ORI-treated group. CHIR could attenuate the effects of ORI in SW1990 cells. We established a mice model by injecting 1 × 106 SW1990 cells into nude mice intraperitoneally to test whether ORI affects tumour metastasis. Metastatic formation was inhibited by ORI (5 and 10 mg/kg) compared with the control group. Tumour sections stained with anti-E-cadherin, anti-vimentin and anti-β-catenin antibodies revealed that ORI inhibited EMT, as well as the Wnt/β-catenin pathway in vivo.

Conclusions

ORI can inhibit pancreatic cancer cell SW1990 migration and EMT by down-regulating Wnt/β-catenin signal transduction in vitro and in vivo. Therefore, it can be potentially and effectively used in the clinical management of pancreatic cancer.
Literature
1.
2.
3.
Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442–54.CrossRefPubMed
4.
Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90.CrossRefPubMed
5.
Rasheed ZA, Yang J, Wang Q, et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst. 2010;102(5):340–51.CrossRefPubMedPubMedCentral
6.
Blackford A, Serrano OK, Wolfgang CL, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res. 2009;15(14):4674–9.CrossRefPubMedPubMedCentral
7.
Yang MH, Chen CL, Chau GY, et al. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology. 2009;50(5):1464–74.CrossRefPubMed
8.
Araki K, Shimura T, Suzuki H, et al. E/N-cadherin switch mediates cancer progression via TGF-beta-induced epithelial-to mesenchymal transition in extrahepatic cholangiocarcinoma. Br J Cancer. 2011;105(12):1885–93.CrossRefPubMedPubMedCentral
9.
Sun HD, Huang SX, Han QB. Diterpenoids from Isodon species and their biological activities. Nat Prod Rep. 2006;23:673–98.CrossRefPubMed
10.
Huang J, Wu L, Tashiro S, et al. Reactive oxygen species mediate oridonin-induced HepG2 apoptosis through p53, MAPK and mitochondrial signaling pathways. J Pharmacol Sci. 2008;107:370–9.CrossRefPubMed
11.
Cheng Y, Qiu F, Ye YC, et al. Oridonin induces G2/M arrest and apoptosis via activating ERK-p53 apoptotic pathway and inhibiting PTK-RAS-RAFJNK survival pathway in murine fibrosarcoma L929 cells. Arch Biochem Biophys. 2009;490:70–5.CrossRefPubMed
12.
Gao FH, Hu XH, Li W, et al. Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer. 2010;10:610.CrossRefPubMedPubMedCentral
13.
Kyriazis AP, McCombs WB 3rd, Sandberg AA, et al. Establishment and characterization of human pancreatic adenocarcinoma cell line SW-1990 in tissue culture and the nude mouse. Cancer Res. 1983;43(9):4393–401.PubMed
14.
Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 2003;15:740–6.CrossRefPubMed
15.
Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol. 2003;129:199–221.PubMed
16.
Nakamura T, Hamada F, Ishidate T, et al. Axin, an inhibitor of the Wnt signalling pathway, interacts with beta-catenin, GSK-3 beta and APC and reduces the beta-catenin level. Genes Cells. 1998;3:395–403.CrossRefPubMed
17.
Cross DA, Alessi DR, Cohen P, et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785–9.CrossRefPubMed
18.
Bikkavilli RK, Feigin ME, Malbon CC. p38 mitogen-activated protein kinase regulates canonical Wnt/beta-catenin signaling by inactivation of GSK3beta. J Cell Sci. 2008;121:3598–607.CrossRefPubMed
19.
Guo Y, Shan Q, Gong Y, et al. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway. Cancer Biol Ther. 2012;13:1244–54.CrossRefPubMedPubMedCentral
20.
Yang J, Jiang H, Wang C, et al. Oridonin triggers apoptosis in colorectal carcinoma cells and suppression of microRNA-32 expression augments oridonin-mediated apoptotic effects. Biomed Pharmacother. 2015;72:125–34.CrossRefPubMed
21.
Xu B, Shen W, Liu X, et al. Oridonin inhibits BxPC-3 cell growth through cell apoptosis. Acta Biochim Biophys Sin (Shanghai). 2015;47:164–73.CrossRef
22.
Zhang XH, Liu YX, Jia M, et al. Oridonin inhibits tumor growth in glioma by inducing cell cycle arrest and apoptosis. Cell Mol Biol (Noisy-le-grand). 2014;60:29–36.
23.
Dong Y, Zhang T, Li J, et al. Oridonin inhibits tumor growth and metastasis through anti-angiogenesis by blocking the Notch signaling. PLoS One. 2014;9:e113830.CrossRefPubMedPubMedCentral
24.
Li YC, Sun MR, Zhao YH, et al. Oridonin suppress cell migration via regulation of nonmuscle myosin IIA. Cytotechnology. 2016;68(3):389–97.CrossRefPubMed
25.
Wang S, Zhong Z, Wan J, et al. Oridonin induces apoptosis, inhibits migration and invasion on highly-metastatic human breast cancer cells. Am J Chin Med. 2013;41(1):177–96.CrossRefPubMed
26.
Ren KK, Wang HZ, Xie LP, et al. The effects of oridonin on cell growth, cell cycle, cell migration and differentiation in melanoma cells. J Ethnopharmacol. 2006;103(2):176–80.CrossRefPubMed
27.
28.
29.
30.
31.
Kokkinos MI, Wafai R, Wong MK, et al. Vimentin and epithelial-mesenchymal transition in human breast cancer-observations in vitro and in vivo. Cells Tissues Organs. 2007;185(1–3):191–203.CrossRefPubMed
32.
Cheng GZ, Chan J, Wang Q, et al. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res. 2007;67:1979–87.CrossRefPubMed
33.
Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7:131–42.CrossRefPubMed
34.
Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004;118:277–9.CrossRefPubMed
35.
Zhou Z, Wang S, Song C, et al. Paeoniflorin prevents hypoxia-induced epithelial-mesenchymal transition in human breast cancer cells. Onco Targets Ther. 2016;9:2511–8.CrossRefPubMedPubMedCentral
36.
Cui Y, Wang Y, Li H, et al. Asparaginyl endopeptidase promotes the invasion and metastasis of gastric cancer through modulating epithelial-to-mesenchymal transition and analysis of their phosphorylation signaling pathways. Oncotarget. 2016. doi:10.​18632/​oncotarget.​8879.
37.
Nusse R. The Wnt gene family in tumorigenesis and in normal development. J Steroid Biochem Mol Biol. 1992;43(1–3):9–12.CrossRefPubMed
38.
Bullions LC, Levine AJ. The role of beta-catenin in cell adhesion, signal transduction and cancer. Curr Opin Oncol. 1998;10(1):81–7.CrossRefPubMed
39.
40.
Tanaka Y, Kato K, Notohara K, et al. Frequent beta-catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solid-pseudopapillary neoplasm. Cancer Res. 2001;61(23):8401–4.PubMed
41.
Liu Y, Liu YZ, Zhang RX, et al. Oridonin inhibits the proliferation of human osteosarcoma cells by suppressing Wnt/β-catenin signaling. Int J Oncol. 2014;45(2):795–803.PubMed
Metadata
Title
Oridonin inhibits pancreatic cancer cell migration and epithelial-mesenchymal transition by suppressing Wnt/β-catenin signaling pathway
Authors
Qian-Qian Liu
Ke Chen
Qiao Ye
Xiao-Hua Jiang
Yun-Wei Sun
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2016
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-016-0336-z

Other articles of this Issue 1/2016

Cancer Cell International 1/2016 Go to the issue

Erratum

Erratum to: Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth

Primary research

Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth

Primary research

Topoisomerase IIβ mediates the resistance of glioblastoma stem cells to replication stress-inducing drugs

Primary research

Schedule-dependent increased efficiency of pemetrexed-ionizing radiation combination therapy elicits a differential DNA damage response in lung cancer cells

Retraction Note

Retraction Note to: Diagnosis, classification and grading of canine mammary tumours as a model to study human breast cancer: an Clinico-Cytohistopathological study with environmental factors influencing public health and medicine

Primary research

Long non-coding RNA DBCCR1-003 regulate the expression of DBCCR1 via DNMT1 in bladder cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits